Mersana Therapeutics, Inc.
Mersana Therapeutics is dedicated to discovering and developing innovative antibody-drug conjugates (ADCs) for cancer treatment. Their mission is to create life-changing therapies for patients fighting cancer by leveraging proprietary technology platforms that allow for customization and optimization of ADCs. The company focuses on both cytotoxic and immunostimulatory payloads to address unmet medical needs and improve efficacy and tolerability in cancer therapies.
Industries
Nr. of Employees
medium (51-250)
Mersana Therapeutics, Inc.
Patents
Products
Emi-Le (XMT-1660)
B7-H4-directed antibody-drug conjugate developed with a target-optimized DAR (DAR 6) using a homogeneous payload platform; being evaluated in multicenter Phase 1 trials for multiple solid tumor indications.
XMT-2056
HER2-directed STING-agonist antibody-drug conjugate designed to target a novel HER2 epitope and locally activate STING signaling in tumor-resident immune cells and tumor cells; under Phase 1 evaluation and granted orphan drug designation for gastric cancer.
Upifitamab rilsodotin (XMT-1536)
NaPi2b-directed antibody-drug conjugate developed on a polymer-based platform that has been evaluated in Phase 1/2 studies, including combination and expansion cohorts for ovarian cancer.
Emi-Le (XMT-1660)
B7-H4-directed antibody-drug conjugate developed with a target-optimized DAR (DAR 6) using a homogeneous payload platform; being evaluated in multicenter Phase 1 trials for multiple solid tumor indications.
XMT-2056
HER2-directed STING-agonist antibody-drug conjugate designed to target a novel HER2 epitope and locally activate STING signaling in tumor-resident immune cells and tumor cells; under Phase 1 evaluation and granted orphan drug designation for gastric cancer.
Upifitamab rilsodotin (XMT-1536)
NaPi2b-directed antibody-drug conjugate developed on a polymer-based platform that has been evaluated in Phase 1/2 studies, including combination and expansion cohorts for ovarian cancer.
Services
Partnership agreements to co-develop ADC candidates using internal ADC platforms with options for licensing and co-commercialization.
Partnership agreements to co-develop ADC candidates using internal ADC platforms with options for licensing and co-commercialization.
Expertise Areas
- ADC platform development
- Payload chemistry and linker engineering
- Preclinical in vivo pharmacology
- Clinical trial management (Phase 1 dose escalation and expansion)
Key Technologies
- Antibody-drug conjugates (ADCs)
- Site-specific antibody conjugation
- Drug-to-antibody ratio (DAR) optimization
- Polymer-based linker platforms